Post-vaccine nodules with prurigo in a child successfully treated by dupilumab.

We report the case of a 7-year-old girl with severe generalized prurigo associated with diffuse persistent pruritic nodules due to sensitization to aluminum-adsorbed vaccines. Treatment with dupilumab resulted in an excellent therapeutic response.

Real-life management of psoriasis with biological agents during pregnancy.

Background: French guidelines recommend stopping biologic treatment of psoriasis between 3 and 24 weeks before conception in accordance with the relevant Summary of Product Characteristics (SmPC). The aim of this study was to evaluate the real-life practice of dermatologists in the management of pregnant women with psoriasis previously treated with biologic agents. We wished to assess the level of practitioner adherence to the relevant SmPCs.

Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance.

Background: There are limited data regarding the long-term continuation with biological therapy for patients with psoriasis. In particular, the reasons for secukinumab discontinuation have not been thoroughly investigated.

Aim: To better ascertain the real-life continuation of secukinumab in psoriasis, we conducted a retrospective study to evaluate the incidence, causes and factors of secukinumab discontinuation in patients with psoriasis.

Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients.

Background: Biological agents targeting IL-17 are very effective for clearing moderate to severe psoriasis. There is limited information regarding the frequency and pattern of psoriasis relapse upon treatment cessation.

Objective: To investigate the pattern of psoriasis recurrence in patients who were treated with brodalumab following Amgen's decision to stop the clinical programme in June 2015.

Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study.

Background: There is limited information about active tuberculosis (TB) occurring in psoriasis patients treated with Tumor necrosis factor (TNF) antagonists.

Objective: To describe the clinical characteristics of TB in psoriasis patients treated with TNF antagonists.

Methods: Nationwide retrospective study of psoriasis patients having experienced TB.